Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), also called pancreatic cancer is predicted to become the 2nd frequent cause of cancer related death by 2030 (1,2). Recent studies have found that the tumor microenvironment characterized by ample stromal cells and a complex extracellular matrix composition are the main contributing factors. Genetic mutations such as point mutations, insertions, deletions, amplifications, translocations, fusions and inversions are frequently seen in PDACS.

pancreatic-cancer img

Genes mutated in PDAC

KRAS TP53 CDKN2A SMAD4 RNF43 ARID1A BRCA1 GNAS BRCA2 TGFBR2

OriGene has the largest collection Mutant ORF Clones that are conveniently cloned in mammalian expression and dual tagging vector and is available as transfection ready DNA. In addition, here are other tools for analyzing genes associated with PDAC.

Mutant ORF clones Antibodies
(Ultra-specific & monoclonals) 		OEL control
(controls for WB) 		CytoSections
(controls for IHC, ICC)
KRAS - Mutants KRAS - Antibodies KRAS – Overexpression lysates KRAS - CytoSections
TP53 - Mutants TP53 - Ultra-specific Antibodies TP53 – Overexpression lysates TP53 - CytoSections
CDKN2A - Mutants CDKN2A - Antibodies CDKN2A – Overexpression lysates CDKN2A - CytoSections
SMAD4 - Antibodies SMAD4 – Overexpression lysates SMAD4 - CytoSections
RNF43 - Antibodies RNF43 – Overexpression lysates RNF43 - CytoSections
ARID1A - Antibodies ARID1A – Overexpression lysates ARID1A - CytoSections
BRCA1 – mutants BRCA1 – Antibodies BRCA1 - CytoSections
GNAS - Mutants GNAS - Antibodies GNAS – Overexpression lysates GNAS - CytoSections
BRCA2 – mutants BRCA2 - Antibodies BRCA2 – Overexpression lysates BRCA2 - CytoSections
TGFBR2 - Antibodies TGFBR2 – Overexpression lysates TGFBR2 - CytoSections


Pancreatic cancer tissue controls

Frozen sections Tissue Protein Lysates Total RNA FFPE Sections Genomic DNA Tissue Scan

References:

  1. Sun H, Zhang B, Li H. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment. Technol Cancer Res Treat. 2020;19.
  2. Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018,8(9)